Results	results	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
comparative	comparative	O	O	O	O
,	,	O	O	O	O
phase	phase	O	O	O	O
III	iii	O	O	O	O
,	,	O	O	O	O
12-week	12-week	O	O	O	O
,	,	O	O	O	O
multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
assessment	assessment	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
tolerability	tolerability	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
fixed-dose	fixed-dose	O	O	O	O
combination	combination	O	O	O	O
of	of	O	O	O	O
telmisartan	telmisartan	O	O	OTHERS	I
and	and	O	O	O	O
amlodipine	amlodipine	O	O	OTHERS	I
versus	versus	O	O	O	O
amlodipine	amlodipine	O	O	OTHERS	I
monotherapy	monotherapy	O	O	O	O
in	in	O	O	O	O
Indian	indian	O	O	O	O
adults	adults	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
II	ii	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
evaluate	evaluate	O	O	O	O
the	the	O	O	O	O
efficacy	efficacy	O	O	O	O
and	and	O	O	O	O
tolerability	tolerability	O	O	O	O
of	of	O	O	O	O
a	a	O	O	O	O
new	new	O	O	O	O
fixed-dose	fixed-dose	O	O	O	O
combination	combination	O	O	O	O
(	(	O	O	O	O
FDC	fdc	O	O	O	O
)	)	O	O	O	O
of	of	O	O	O	O
telmisartan	telmisartan	O	O	OTHERS	I
40	40	O	O	O	O
mg	mg	O	O	OTHERS	I
+	+	O	O	O	O
amlodipine	amlodipine	O	O	OTHERS	I
5	5	O	O	O	O
mg	mg	O	O	OTHERS	I
(	(	O	O	O	O
T+A	t+a	O	O	O	O
)	)	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
amlodipine	amlodipine	O	O	OTHERS	I
5-mg	5-mg	O	O	O	O
monotherapy	monotherapy	O	O	O	O
(	(	O	O	O	O
A	a	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
adult	adult	O	O	O	O
Indian	indian	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
II	ii	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
This	this	O	O	O	O
comparative	comparative	O	O	O	O
,	,	O	O	O	O
Phase	phase	O	O	O	O
III	iii	O	O	O	O
,	,	O	O	O	O
12-week	12-week	O	O	O	O
,	,	O	O	O	O
multicenter	multicenter	O	O	O	O
,	,	O	O	O	O
prospective	prospective	O	O	O	O
,	,	O	O	O	O
randomized	randomized	O	O	O	O
,	,	O	O	O	O
double-blind	double-blind	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
conducted	conducted	O	O	O	O
in	in	O	O	O	O
Indian	indian	O	O	O	O
patients	patients	O	O	O	O
aged	aged	O	O	O	O
18	18	O	O	O	O
to	to	O	O	O	O
65	65	O	O	O	O
years	years	O	O	O	O
with	with	O	O	O	O
established	established	O	O	O	O
stage	stage	O	O	O	O
II	ii	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Patients	patients	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
oral	oral	O	O	O	O
FDC	fdc	O	O	O	O
of	of	O	O	O	O
T+A	t+a	O	O	O	O
or	or	O	O	O	O
A	a	O	O	O	O
QD	qd	O	O	O	O
before	before	O	O	O	O
breakfast	breakfast	O	O	O	O
for	for	O	O	O	O
12	12	O	O	O	O
weeks	weeks	O	O	O	O
;	;	O	O	O	O
blood	blood	O	O	O	O
pressure	pressure	O	O	O	O
(	(	O	O	O	O
BP	bp	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
heart	heart	O	O	O	O
rate	rate	O	O	O	O
were	were	O	O	O	O
measured	measured	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
sitting	sitting	O	O	O	O
position	position	O	O	O	O
.	.	O	O	O	O

Primary	primary	O	O	O	O
efficacy	efficacy	O	O	O	O
end	end	O	O	O	O
points	points	O	O	O	O
were	were	O	O	O	O
reduction	reduction	O	O	O	O
in	in	O	O	O	O
clinical	clinical	O	O	O	O
systolic	systolic	O	O	O	O
BP	bp	O	O	O	O
(SBP)/	(sbp)/	O	O	O	O
diastolic	diastolic	O	O	O	O
BP	bp	O	O	O	O
(	(	O	O	O	O
DBP	dbp	O	O	O	O
)	)	O	O	O	O
from	from	O	O	O	O
baseline	baseline	O	O	O	O
to	to	O	O	O	O
study	study	O	O	O	O
end	end	O	O	O	O
and	and	O	O	O	O
number	number	O	O	O	O
of	of	O	O	O	O
responders	responders	O	O	O	O
(	(	O	O	O	O
ie	ie	O	O	OTHERS	I
,	,	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
achieved	achieved	O	O	O	O
target	target	O	O	O	O
SBP/	sbp/	O	O	O	O
DBP	dbp	O	O	O	O
<	<	O	O	O	O
130/<80	130/<80	O	O	O	O
mm	mm	O	O	OTHERS	I
Hg	hg	O	O	OTHERS	I
)	)	O	O	O	O
at	at	O	O	O	O
end	end	O	O	O	O
of	of	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Tolerability	tolerability	O	O	O	O
was	was	O	O	O	O
assessed	assessed	O	O	O	O
by	by	O	O	O	O
treatment-emergent	treatment-emergent	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
,	,	O	O	O	O
identified	identified	O	O	O	O
using	using	O	O	O	O
physical	physical	O	O	O	O
examination	examination	O	O	O	O
,	,	O	O	O	O
laboratory	laboratory	O	O	O	O
analysis	analysis	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
electrocardiography	electrocardiography	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
A	a	O	O	O	O
total	total	O	O	O	O
of	of	O	O	O	O
210	210	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
enrolled	enrolled	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
;	;	O	O	O	O
203	203	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
143	143	O	O	O	O
men	men	O	O	O	O
,	,	O	O	O	O
60	60	O	O	O	O
women	women	O	O	O	O
)	)	O	O	O	O
completed	completed	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
while	while	O	O	O	O
7	7	O	O	O	O
were	were	O	O	O	O
lost	lost	O	O	O	O
to	to	O	O	O	O
follow-up	follow-up	O	O	O	O
(	(	O	O	O	O
4	4	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
T+A	t+a	O	O	O	O
group	group	O	O	O	O
and	and	O	O	O	O
3	3	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
A	a	O	O	O	O
group	group	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
considered	considered	O	O	O	O
with-drawn	with-drawn	O	O	O	O
.	.	O	O	O	O

At	at	O	O	O	O
study	study	O	O	O	O
end	end	O	O	O	O
,	,	O	O	O	O
statistically	statistically	O	O	O	O
significant	significant	O	O	O	O
percentage	percentage	O	O	O	O
reductions	reductions	O	O	O	O
from	from	O	O	O	O
baseline	baseline	O	O	O	O
within	within	O	O	O	O
groups	groups	O	O	O	O
and	and	O	O	O	O
between	between	O	O	O	O
groups	groups	O	O	O	O
were	were	O	O	O	O
observed	observed	O	O	O	O
in	in	O	O	O	O
SBP	sbp	O	O	O	O
(	(	O	O	O	O
T+A	t+a	O	O	O	O
[	[	O	O	O	O
-27.4	-27.4	O	O	O	O
%	%	O	O	O	O
]	]	O	O	O	O
;	;	O	O	O	O
A	a	O	O	O	O
[	[	O	O	O	O
-16.6	-16.6	O	O	O	O
%	%	O	O	O	O
]	]	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
DBP	dbp	O	O	O	O
(	(	O	O	O	O
T+A	t+a	O	O	O	O
[	[	O	O	O	O
-20.1	-20.1	O	O	O	O
%	%	O	O	O	O
]	]	O	O	O	O
;	;	O	O	O	O
A	a	O	O	O	O
[	[	O	O	O	O
-13.3	-13.3	O	O	O	O
%	%	O	O	O	O
]	]	O	O	O	O
)	)	O	O	O	O
(	(	O	O	O	O
all	all	O	O	O	O
,	,	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Response	response	O	O	O	O
rates	rates	O	O	O	O
were	were	O	O	O	O
87.3	87.3	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
89/102	89/102	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
T+A	t+a	O	O	O	O
group	group	O	O	O	O
and	and	O	O	O	O
69.3	69.3	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
70/101	70/101	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
A	a	O	O	O	O
group	group	O	O	O	O
(	(	O	O	O	O
P	p	O	O	OTHERS	I
<	<	O	O	O	O
0.05	0.05	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
prevalences	prevalences	O	O	O	O
of	of	O	O	O	O
adverse	adverse	O	O	O	O
events	events	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
significantly	significantly	O	O	O	O
different	different	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
2	2	O	O	O	O
treatment	treatment	O	O	O	O
groups	groups	O	O	O	O
(	(	O	O	O	O
T+A	t+a	O	O	O	O
,	,	O	O	O	O
16.0	16.0	O	O	O	O
%	%	O	O	O	O
[	[	O	O	O	O
17/106	17/106	O	O	O	O
]	]	O	O	O	O
;	;	O	O	O	O
A	a	O	O	O	O
,	,	O	O	O	O
15.4	15.4	O	O	O	O
%	%	O	O	O	O
[	[	O	O	O	O
16/104	16/104	O	O	O	O
]	]	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Peripheral	peripheral	O	O	O	O
edema	edema	O	DISEASE	OTHERS	I
was	was	O	O	O	O
reported	reported	O	O	O	O
in	in	O	O	O	O
8.5	8.5	O	O	O	O
%	%	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
9/106	9/106	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
T+A	t+a	O	O	O	O
group	group	O	O	O	O
compared	compared	O	O	O	O
with	with	O	O	O	O
13.5	13.5	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
14/104	14/104	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
A	a	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
cough	cough	O	O	OTHERS	I
was	was	O	O	O	O
reported	reported	O	O	O	O
in	in	O	O	O	O
3.8	3.8	O	O	O	O
%	%	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
4/106	4/106	O	O	O	O
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
T+A	t+a	O	O	O	O
group	group	O	O	O	O
and	and	O	O	O	O
1.0	1.0	O	O	O	O
%	%	O	O	O	O
(	(	O	O	O	O
1/104	1/104	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
A	a	O	O	O	O
group	group	O	O	O	O
;	;	O	O	O	O
these	these	O	O	O	O
differences	differences	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
reach	reach	O	O	O	O
statistical	statistical	O	O	O	O
significance	significance	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidences	incidences	O	O	O	O
of	of	O	O	O	O
headache	headache	O	DISEASE	OTHERS	I
,	,	O	O	O	O
dizziness	dizziness	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
diarrhea	diarrhea	O	DISEASE	OTHERS	I
were	were	O	O	O	O
similar	similar	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
2	2	O	O	O	O
groups	groups	O	O	O	O
.	.	O	O	O	O

CONCLUSIONS	conclusions	O	O	O	O
:	:	O	O	O	O
Among	among	O	O	O	O
these	these	O	O	O	O
Indian	indian	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
stage	stage	O	O	O	O
II	ii	O	O	O	O
hypertension	hypertension	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
FDC	fdc	O	O	O	O
of	of	O	O	O	O
T+A	t+a	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
significantly	significantly	O	O	O	O
more	more	O	O	O	O
effective	effective	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
regard	regard	O	O	O	O
to	to	O	O	O	O
BP	bp	O	O	O	O
reductions	reductions	O	O	O	O
,	,	O	O	O	O
than	than	O	O	O	O
A	a	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
both	both	O	O	O	O
treatments	treatments	O	O	O	O
were	were	O	O	O	O
well	well	O	O	O	O
tolerated	tolerated	O	O	O	O
.	.	O	O	O	O

